This Article Abstract Full Text Full Text (PDF) Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wang, J Z Articles by Mayr, N A Search for Related Content PubMed PubMed Citation Articles by Wang, J Z Articles by Mayr, N A

Dose escalation to combat hypoxia in prostate cancer: a radiobiological study on clinical data

¹ Department of Radiation Medicine, The Ohio State University, Columbus, OH 43210, ² Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI 53226, USA

View larger version (18K): [in a new window]   Figure 1. 2 year biologically no evidence of disease(bNED) versus prescription dose of 125I brachytherapy. The symbols represent the Fox Chase clinical data [1] and the curves represent the model calculations. The three points (circle, square and triangle), as well as the three curves (solid, dashed and dash-dotted), are for patient groups with hypoxic, mixed and aerated prostate tumours, respectively. The prescription dose of the clinical data was 145 Gy of 125I implant. The vertical dotted line indicates the prescription dose for the hypoxic group to achieve a bNED of 81%. The vertical error bar shows the standard confidence interval (CI) of the clinical data for the hypoxic group (the CIs for the other two groups are not shown) and the horizontal error bar shows the CI of dose escalation for the hypoxic group to achieve a target bNED of 81%.

View larger version (17K): [in a new window]   Figure 2. (a) Tumour control probability (TCP) as a function of the fraction of tumour hypoxia (fh) for individual patients of prostate cancer. The prescription dose is 145 Gy for 125I brachytherapy. (b) Dose escalation of 125I brachytherapy required overcoming tumour hypoxia (to achieve a TCP of 81%) as a function of hypoxia fraction fh.